By proceeding, you agree to our Terms of Use and Privacy Policy.
A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
21-22 September 2022
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine.
Event Ended
USA
Paid
Boston
26-28 September 2022
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging
26-29 September 2022
Marrying Complex Biomarker Validation & CDx Development for Supercharged Precision Oncology Pipeline Commercialization The 12th World Clinical Biomarkers & CDx Summit returns at a crucial time for the entire precision & targeted drug development indu
06-08 March 2023
For almost 3 decades, the Molecular & Precision Med TRI-CON has served as the leading international meeting place for the diagnostics and precision medicine community.
Hybrid
San Diego
05-08 September 2023
Welcome to the 13th Annual World Clinical Biomarkers & CDx Summit, the highly anticipated gathering that brings together over 600 senior decision makers in the field of biomarkers and companion diagnostics (CDx). This industry-led meeting aims to acc
26-28 September 2023
5th Annual RAS-Targeted Drug Development SummitPersonalizing Medicine Via Targeting Oncogenic RAS for CancerWith the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable!